Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments.
SHL Telemedicine's 3-Year RORE % for the quarter that ended in Dec. 2025 was 14.56%.
The industry rank for SHL Telemedicine's 3-Year RORE % or its related term are showing as below:
SHMLF's 3-Year RORE % is ranked better than 62.38% of 606
companies
in the Healthcare Providers & Services industry
Industry Median: 0.195
vs SHMLF: 14.56
Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.
There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 3-year period is chosen.
Be Aware
Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.
SHL Telemedicine 3-Year RORE % Related Terms
SHL Telemedicine 3-Year RORE % Historical Data
* Premium members only.
The historical data trend for SHL Telemedicine's 3-Year RORE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SHMLF vs VEEV, BTSG, TEM: 3-Year RORE % Comparison
For the Health Information Services subindustry, SHL Telemedicine's 3-Year RORE %, along with its competitors' market caps and 3-Year RORE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
SHL Telemedicine 3-Year RORE % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, SHL Telemedicine's 3-Year RORE % distribution charts can be found below:
* The bar in red indicates where SHL Telemedicine's 3-Year RORE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of 3-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Dec. 2025 and 3-year before.
SHL Telemedicine (SHMLF) has a 3-Year RORE % of 14.56 as of Dec. 2025. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on SHL Telemedicine and its competitors. According to the industry distribution chart, SHL Telemedicine ranks #228 out of 606 companies in the Healthcare Providers & Services industry, placing it in the top 37.6%.
Is SHL Telemedicine's 3-Year RORE % too high?
SHL Telemedicine's current 3-Year RORE % is 14.56. The Healthcare Providers & Services industry median 3-Year RORE % is 0.20. SHL Telemedicine's value of 14.56 is 7366.7% above this industry median. Based on the distribution chart, SHL Telemedicine ranks #228 out of 606 companies in the Healthcare Providers & Services industry, which is above the industry midpoint. Overall, SHL Telemedicine has a GF Score™ of 52/100, reflecting its overall financial health beyond just this single metric.
How does SHL Telemedicine's 3-Year RORE % compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, SHL Telemedicine ranks #228 out of 606 companies for 3-Year RORE %. This puts SHL Telemedicine in the upper half of its industry. The industry median 3-Year RORE % is 0.20. SHL Telemedicine's value of 14.56 is 7366.7% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year RORE % for a Healthcare Providers & Services company?
The median 3-Year RORE % among Healthcare Providers & Services companies is 0.20, based on 606 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year RORE % significantly above this median, while those in the bottom quartile fall well below. However, 3-Year RORE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. SHL Telemedicine's current 3-Year RORE % of 14.56 is 7366.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year RORE % mean?
A high 3-Year RORE % can signal that a stock is expensive relative to its fundamentals. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on SHL Telemedicine and its competitors. For the Healthcare Providers & Services industry, the median 3-Year RORE % is 0.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. SHL Telemedicine's current 3-Year RORE % is 14.56. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SHL Telemedicine stock overvalued right now?
SHL Telemedicine (SHMLF) has a current 3-Year RORE % of 14.56. The stock's GF Value™ is $12.09, compared to a current price of $4.84 — trading 59.9% below its estimated fair value. The current 3-Year RORE % is 14.56 and 7366.7% above the Healthcare Providers & Services industry median of 0.20. SHL Telemedicine's overall GF Score™ is 52/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year RORE % calculated?
3-Year RORE % is calculated from a company's financial statements. For SHL Telemedicine (SHMLF), the current 3-Year RORE % is 14.56 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is SHL Telemedicine (SHMLF) Overvalued in 2026?
Based on GuruFocus' analysis, SHL Telemedicine stock appears to be undervalued.
The current stock price of $4.84 is trading 59.9% below its estimated GF Value™ of $12.09.
Key valuation signals for SHMLF:
3-Year RORE %: 14.56
GF Value™: $12.09 vs. price of $4.84 (59.9% below fair value)
Industry Position: 7366.7% above the Healthcare Providers & Services median (#228 of 606)
No single metric tells the full story. See the SHMLF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
SHL Telemedicine Ltd develops and markets personal telemedicine solutions. The company consists of the transmission of medical data by an individual, from a remote location to a medical call center, through telecommunication networks. The company provides healthcare professional solutions to patients suffering from congestive heart failure, chronic obstructive pulmonary disease, and readmission solutions for reducing heart-related readmissions. In addition, consumer solutions include cardiac monitoring services. The company's geographical segments are Israel, Europe, and the rest of the world, out of which majority of revenue comes from Israel.
52GF Score
Get the complete analysis for SHMLF
3-Year RORE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHMLF has been successfully added to your 
